Osteoclastogenesis Enhancement Assay

PRIMARY OUTCOME

enhanced osteoclastogenesis with anti-CarP antibody-exposed NETs

EXPECTED OUTCOMES

## Expected Outcomes ### Primary Outcomes 1. **Enhanced osteoclastogenesis:** Test condition increases TRAP+ cell number by ≥50% vs RANKL alone 2. **Larger osteoclasts:** Increased average number of nuclei per osteoclast (fusion index) 3. **Enhanced bone resorption:** ≥40% increase in resorbed area on OsteoAssay plates ### Secondary Outcomes - Upregulated osteoclast-specific genes (Trap, Ctsk, Calcr, Nfatc1, c-Fos) - Increased expression of DC-STAMP (cell fusion marker) - Activation of NFATc1, c-Fos transcription factors ### Null Result Interpretation - If no enhancement, test higher concentrations or different time points - May need co-stimulatory factors (M-CSF dose optimization) - Verify BMM differentiation capacity with known enhancer (dexamethasone) as positive control

SUCCESS CRITERIA

## Success Criteria ### Primary - [ ] BMM purity: ≥85% F4/80+/CD11b+ by flow cytometry - [ ] Positive control: RANKL produces ≥100 TRAP+ MNCs/well - [ ] Negative control: M-CSF alone produces <10 TRAP+ cells/well - [ ] Test compound: ≥50% increase in TRAP+ cells vs RANKL alone at optimal dose ### Secondary - [ ] Dose-response: EC50 calculated for test compound - [ ] Gene expression: ≥2-fold Cathepsin K increase at optimal dose - [ ] Resorption assay: ≥40% increase in resorbed area (if performed) ### Technical Quality Gates - [ ] Cell viability > 80% at all concentrations (LDH release) - [ ] Fresh bone marrow for each biological replicate - [ ] TRAP staining optimized (positive control stains deep red) - [ ] ≥3 independent bone marrow isolations (biological replicates) - [ ] Blinded cell counting (analyst unaware of condition)

PROTOCOL

## Protocol: Osteoclastogenesis Enhancement Assay ### Study Design In vitro assay to determine whether a test condition/compound enhances osteoclast differentiation from bone marrow-derived macrophages (BMMs). Model for rheumatoid arthritis bone destruction. ### Cell Culture 1. **Bone marrow isolation:** - Extract femurs/tibias from 8-12 week old mice (C57BL/6J) - Flush bone marrow with α-MEM - Culture in α-MEM + 10% FBS + M-CSF (20 ng/mL) for 3 days to generate BMMs 2. **BMM characterization:** - Verify F4/80+, CD11b+ by flow cytometry - Cell viability > 90% (Trypan blue) ### Osteoclast Differentiation 1. **Standard differentiation cocktail:** - α-MEM + 10% FBS - M-CSF (30 ng/mL) - survival factor - RANKL (50-100 ng/mL) - differentiation factor - Treatment duration: 5-7 days, change media every 2 days 2. **Test condition:** - Add test compound/condition at day 0 - Use multiple concentrations (0.1, 1, 10 µM or ng/mL) - Compare to RANKL alone (positive control) - No RANKL (M-CSF only) as negative control ### Osteoclast Characterization **TRAP Staining:** 1. At day 5-7, fix cells with 4% PFA 2. Stain using Acid Phosphatase Kit (Sigma): - Incubate 30 min at 37°C - Counterstain with hematoxylin 3. Quantify: - TRAP+ multinucleated cells (≥3 nuclei) - Number of nuclei per osteoclast - Area of TRAP+ cells **Bone Resorption Assay (Optional):** 1. Seed BMMs on OsteoAssay plates (crystalline calcium phosphate substrate) 2. Treat with M-CSF + RANKL ± test compound 3. At day 7, stain resorption pits: - 5% sodium hypochlorite to remove cells - Stain with von Kossa or toluidine blue 4. Quantify: % resorbed area per well (ImageJ) **Molecular Markers (qPCR at Day 3, 5, 7):** - Trap (Acp5), Cathepsin K (Ctsk), Calcitonin receptor (Calcr), DC-STAMP (Tm7sf4) - NFATc1 (master regulator of osteoclastogenesis) - Reference genes: Gapdh, β-actin ### Signaling Pathway Analysis 1. **Western blot:** - NFATc1, c-Fos (early osteoclast transcription factors) - p-p38, pERK, pJNK, pAKT (signaling pathways) - NF-κB pathway markers 2. **TRAP/ALP double staining** if examining osteoblast coupling ### Controls - **Positive control:** M-CSF + RANKL (full osteoclastogenesis) - **Negative control:** M-CSF alone (no differentiation) - **Vehicle control:** DMSO or PBS at equivalent concentration - **Reference compound:** Dexamethasone (known enhancer of osteoclastogenesis) or OPG (inhibitor) ### Expected Outcomes 1. **Enhanced TRAP+ cell formation:** Test condition increases number/size of osteoclasts 2. **Upregulated bone resorption:** Increased pit formation on mineral substrate 3. **Increased osteoclast gene expression:** Dose-dependent increase in Trap, Ctsk, Calcr 4. **Pathway activation:** Enhanced phosphorylation of key signaling molecules ### Success Criteria - [ ] BMM purity ≥ 85% F4/80+/CD11b+ by flow cytometry - [ ] RANKL-induced differentiation: ≥100 TRAP+ multinucleated cells per well (positive control) - [ ] M-CSF alone: < 10 TRAP+ cells per well (negative control) - [ ] Dose-response curve: EC50 for test compound determined - [ ] ≥3 biological replicates (independent bone marrow isolations) - [ ] Gene expression validated: ≥2-fold increase in Cathepsin K at optimal dose - [ ] Cell viability maintained > 80% at all test concentrations

HTML iframe

<iframe src="http://scidex.ai/artifact/exp-84c87be2-1549-4484-aae8-23b6cf4dcd63?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Osteoclastogenesis Enhancement Assay](http://scidex.ai/artifact/exp-84c87be2-1549-4484-aae8-23b6cf4dcd63)

Direct URL

http://scidex.ai/artifact/exp-84c87be2-1549-4484-aae8-23b6cf4dcd63

Preview